SRPT Sarepta Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SRPT

Price (delayed)

$18.79

Market cap

$1.98B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.46

Enterprise value

$2.46B

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: 28
Relative Profitability: Rel. Profitability: 27

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and ...

Highlights
Sarepta Therapeutics's quick ratio has soared by 61% YoY and by 10% from the previous quarter
SRPT's debt is down by 23% year-on-year
The EPS has plunged by 156% YoY
The net income has shrunk by 136% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sarepta.com
Peers: GILD NVAX PTCT BCRX

Key stats

What are the main financial stats of SRPT

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
-2.24%
1 week
3.81%
1 month
15.92%
1 year
-6.33%
YTD
-12.69%
QTD
4.56%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.97B
Gross profit
$1.17B
Operating income
-$143.25M
Net income
-$136.73M
Gross margin
59.1%
Net margin
-6.9%
SRPT's net margin has dropped by 200% year-on-year
The net income has shrunk by 136% YoY
SRPT's gross profit is down by 41% year-on-year and by 15% since the previous quarter
Sarepta Therapeutics's gross margin has decreased by 25% YoY and by 6% from the previous quarter

Price vs fundamentals

How does SRPT's price correlate with its fundamentals

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
SRPT P/E details
P/E
N/A
P/B
1.3
P/S
1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.25
The EPS has plunged by 156% YoY
SRPT's P/B is 87% below its 5-year quarterly average of 10.3 and 13% below its last 4 quarters average of 1.5
The company's equity rose by 13% YoY
The P/S is 86% less than the 5-year quarterly average of 7.0 but 11% more than the last 4 quarters average of 0.9
The revenue fell by 20% YoY and by 10% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROA has plunged by 156% YoY
The return on equity has dropped by 127% year-on-year

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 92% more than the total liabilities
Sarepta Therapeutics's quick ratio has soared by 61% YoY and by 10% from the previous quarter
The company's current ratio has surged by 53% YoY but it fell by 4.5% QoQ
SRPT's debt is 32% smaller than its equity
The debt to equity has declined by 32% year-on-year
SRPT's debt is down by 23% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.